Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Cytokeratin 1/5/10/14 (human) monoclonal antibody (34βE12) (Ready-to-Use)

ENZ-30903 6 ml ~6 µg 194.00 USD
Do you need bulk/larger quantities?
Alternative size available: ENZ-C34903 (0.5ml)

Product Specification

Alternative Name:HMWCK, High molecular weight cytokeratin, Keratin-903
Immunogen:Keratin solubilized from human stratum corneum.
UniProt ID:P04264 (CK1), P13647 (CK5), P13645 (CK10), P02533 (CK14)
Species reactivity:Human
Specificity:34βE12 is specific for “high molecular weight” cytokeratins 1, 5, 10 and 14, corresponding to molecular weights 68, 58, 56.5 and 50 kDa, respectively, which are characteristically found in “complex” epithelium. The antibody reacts with all squamous and ductal epithelium as well as carcinomas such as squamous cell carcinoma and adenocarcinoma of ductal origin (e.g., breast, pancreas) but does not react with sarcoma, melanoma or lymphoma. This antibody reacts with benign small-acinar lesions of the prostate and has been shown to be useful as an adjunct in the identification of prostate carcinoma.
Applications:IHC (PS), WB
Recommended Dilutions/Conditions:Immunohistochemistry (paraffin sections; for optimal results, fixation in alcohol-based fixatives, such as methacarn, is recommended. Pretreatment with proteolytic enzymes such as trypsin may be required when formalin-fixed sections are to be stained. For optimal staining of prostate tissue higher concentrations of protease and longer incubation times are recommended, e.g., 0.5% trypsin at 37°C for 2 to 4 hours. Choose a good quality enzyme-linked anti-mouse IgG1 antibody for detection)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Purity Detail:Affinity purified.
Formulation:Liquid. Ready-to-use solution in PBS containing 0.1% sodium azide and 1% BSA.
Handling:Avoid freeze/thaw cycles.
Shipping:Shipped on Blue Ice
Long Term Storage:+4°C
ENZ-30903 IHC
Immunohistochemistry analysis of human skin tissue using Cytokeratin 1/5/10/14 (human), mAb (34βE12), (Prod. No. ENZ-30903).
ENZ-30903 IHC1
Prostate tissue assayed with Cytokeratin 1/5/10/14 (human) monoclonal antibody (34βE12) (ENZ-30903). Developed with POLYVIEW® PLUS HRP (anti-mouse) reagent (ENZ-ACC104) and HIGHDEF® DAB Chromogen/Substrate Set (ENZ-ACC105).
ENZ-30903 IHC2
Prostate tissue assayed with Cytokeratin 1/5/10/14 (human) monoclonal antibody (34βE12) (ENZ-30903). Developed with POLYVIEW® PLUS HRP (anti-mouse) reagent (ENZ-ACC104) and HIGHDEF® DAB Chromogen/Substrate Set (ENZ-ACC105).
Please mouse over
ENZ-30903 IHC ENZ-30903 IHC1 ENZ-30903 IHC2

Product Literature References

Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia: T.L. Lotan, et al.; Mod. Pathol. 26, 587 (2013), Application(s): Multiplex immunohistochemistry using formalin-fixed, paraffin-embedded human prostate carcinoma tissue samples, Abstract; Full Text
Immunohistochemical markers for the differential diagnosis of nephrogenic adenomas: W. Quinones, et al.; Ann. Diagn. Pathol. 17, 41 (2013), Application(s): Immunohistochemistry using formalin-fixed, paraffin-embedded human nephrogenic adenoma tissue samples, Abstract;
Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death: C.M. Heaphy, et al.; Cancer Discov. 3, 1130 (2013), Application(s): Immunohistochemistry multiplexed with fluorescent in-situ hybridization using formalin-fixed, paraffin-embedded human prostate carcinoma tissue samples, Abstract; Full Text
Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung: H. Uramoto, et al.; Anticancer Res. 30, 4717 (2010), Application(s): IHC using human lung cancer (ADSQ) samples, Abstract; Full Text
Somatic but Not Germline Mutation of the APC Gene in a Case of Cribriform-Morular Variant of Papillary Thyroid Carcinoma: J. Cameselle-Teijeiro, et al.; Am. J. Clin. Pathol. 115, 486 (2001), Application(s): IHC using human thyroid carcinoma samples, Abstract; Full Text
Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18: D. Bello, et al.; Carcinogenesis 18, 1215 (1997), Application(s): ICC using human prostate cell lines RWPE-1 and -2, Abstract; Full Text
Metaplastic Shadow Cells in Rectal Adenocarcinoma: Report of a Case With Immunohistochemical Study: H. Nakayama, et al.; Jpn. J. Clin. Oncol. 27, 427 (1997), Application(s): IHC using human rectal adenocarcinoma, Abstract; Full Text
Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma: L. Hedrick & J.I. Epstein; Am. J. Surg. Pathol. 13, 389 (1989), Abstract;
Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: an immunohistochemical study: D.J. Grignon, et al.; Hum. Pathol. 19, 1425 (1988), Abstract;
Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues: A.M. Gown & A.M. Vogel; Am. J. Pathol. 114, 309 (1984), Abstract; Full Text
Monoclonal antibodies to intermediate filament proteins of human cells: unique and cross-reacting antibodies: A.M. Gown & A.M. Vogel; J. Cell Biol. 95, 414 (1982), Abstract; Full Text

Related Products

Cytokeratin 8 (human) monoclonal antibody (35βH11) (Ready-to-Use) 

IHC (PS), WB | Print as PDF
ENZ-30902 6 ml ~6 µg 204.00 USD
Do you need bulk/larger quantities?

Cytokeratin 1/5/10/14 (human) monoclonal antibody (34βE12) 

IHC (PS), WB | Print as PDF
ENZ-C34903 0.5 ml ~10 µg 226.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
Cytokeratin Monoclonal antibody
By catalog section:


Technical Service
Customer Service

Recommend this page

For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2019 Enzo Life Sciences, Inc.,